New Zealand markets open in 1 hour 27 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0200-1.1500 (-27.58%)
At close: 04:00PM EDT
3.0400 +0.02 (+0.66%)
After hours: 04:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1700
Open3.0300
Bid2.9800 x 100
Ask3.0800 x 100
Day's range3.0000 - 3.2400
52-week range2.2100 - 12.0000
Volume762,514
Avg. volume194,516
Market cap28.901M
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-4.0000
Earnings date14 May 2024 - 20 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est31.67
  • PR Newswire

    NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

    NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that (the "Company") has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550(a)(2) and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.

  • PR Newswire

    NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additiona

  • PR Newswire

    NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.